Alzheimer's and Parkinson's diseases are two of the most prominent and complex progressive neurological disorders that have a profound global impact [1,2]. These diseases affect millions of individuals worldwide, causing significant morbidity and placing a substantial burden on healthcare systems and society [3,6]. Despite considerable advancements in understanding these disorders over the years, developing effective treatments remains a complex and multifaceted challenge [7,8].

While much of research progress has been achieved in last century on Alzheimer’s Disease (AD), the conclusive therapy for the same is still unachieved. Several lines of therapeutic regimes have been introduced, which basically act on slowing down the disease progression.

Parkinson’s disease (PD) is the second most common neurodegenerative disease, manifesting as a characteristic movement disorder with a number of additional non-motor features. The pathological hallmark of PD is the presence of intra-neuronal aggregates of a-synuclein (Lewy bodies). The movement disorder of PD occurs largely due to loss of dopaminergic neurons of the substantia nigra, resulting in striatal dopamine depletion.

Alzheimer’s disease (AD) is a global health crisis currently afflicting ~6 million Americans (and ~40 million people worldwide). By the middle of the century, these numbers will stagger by ~16 million Americans (and ~152 million people worldwide) suffering from AD, if breakthrough disease-modifying treatments are not discovered.

Parkinson’s disease is a multifaceted illness that requires interdisciplinary approach to be fully addressed. The etiology of the disease is not completely understood, but genetic and environmental cues play important roles. Histological hallmarks of the disease are the accumulation of alpha-synuclein aggregates, mitochondrial changes and loss of dopaminergic neurons in the substantia nigra.